Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel treatment options for metabolic disorders reported in recent patents

March 6, 2008

FDA grants priority review for GlaxoSmithKline's Promacta/Revolade for ITP

March 6, 2008

Vivus completes patient enrollment in EQUATE (OB-301) trial

March 6, 2008

NeuroSearch reports positive and confirmatory results from TIPO-2 trial

March 5, 2008

Paladin files new drug submission for Seasonique in Canada

March 5, 2008

NicOx initiates two studies for naproxcinod in hypertensive osteoarthritis patients

March 4, 2008

Savient reports further information regarding the negative results in phase III trials of Puricase

March 4, 2008

Living Cell Technologies and Barbara Davis Center to collaborate on diabetes clinical trial program

March 4, 2008

Enrollment completed in proof-of-concept trial for MB-07803 in type 2 diabetes

March 3, 2008

Recent patents disclose novel treatment options for obesity and metabolic disorders

March 3, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...